Importantly, the engineered OMV-PD-1 can bind to PD-L1 on the tumor cell surface and facilitate its internalization, thereby protecting T cells from the PD-1/PD-L1 immune inhibitory axis. The gene discussed is CD274; the disease is neoplasm.